Lumos Pharma — NewLink Genetics — Q3 2016 Earnings Presentation
6 slides from Lumos Pharma's earnings presentation, Nov 1, 2016
Slide 1: Third Quarter 2016 Financial Results
NewLink Genetics Corporation Nasdaq: NLNK November 1, 2016 Third Quarter 2016 Financial Results
Slide 2: Cautionary Note Regarding Forward Looking Statements
Cautionary Note Regarding Forward Looking Statements This presentation contains forward-looking statements of NewLink that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, within the
Slide 3: Investor Day – Distinguished Speakers
Investor Day – Distinguished Speakers IDO Combinations with Checkpoint Inhibitors George C. Prendergast, PhD, President & Chief Executive Officer, Lankenau Institute for Medical Research (LIMR), Editor-in-Chief, Cancer Research 3 Immunoregulatory Role of Tryptophan Metabolism David H. Munn, MD, Medi
Slide 4: NewLink Genetics Investor Day Takeaways
4 NewLink Genetics Investor Day Takeaways IDO pathway is central to immune escape IDO pathway is becoming increasingly validated as a target for drugs Two promising candidates that target the IDO pathway, with distinct mechanisms of action GDC-0919, which targets the enzyme directly (partner
Slide 5: Indoximod Strategy
Indoximod Strategy 5 Optimize Formulation, Enhance Commercial Opportunity and Extend Lifecycle *Includes indoximod, epacadostat and GDC-0919 Next 6-12 Months Updated clinical data for indoximod in melanoma, brain and pancreas cancers Formulation improvements to optimize clinical and commercial p
Slide 6: Financial Position
Financial Position Cash and Equivalents $148 million (September 30, 2016) Debt ~$0.6 million YE 2016 Cash (Projected) ~$132 million Quarterly Negative Cash-Flow ~$13 million Shares Outstanding 29.1 million Market Capitalization $450 million* Headcount 130 6 *As of October 5, 2016